Bioxcel Therapeutics Logo

Innovative Medicine
Backed by the Power of AI

BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience utilizing artificial intelligence.

Innovative Medicine
Backed by the
Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Innovative Medicine
Backed by the Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Our Approach to Drug Development

AI-Driven Transformative Medicines in Neuroscience

We utilize our unique and proprietary AI platform to identify, re-innovate, and develop potential new therapies 

Latest News

Apr 10, 2024
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaVIEW RELEASE
Mar 25, 2024
BioXcel Therapeutics Announces $25 Million Registered Direct OfferingVIEW RELEASE
Mar 15, 2024
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

Apr 12, 2024 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

2.9

CHANGE

0.11 (3.94%)
Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.